B&L To Raise R&D Spending To 10% Of Revenues, Chairman/CEO Zarrella Says
This article was originally published in The Gray Sheet
Bausch & Lomb Chairman and CEO Ronald Zarrella plans to increase R&D spending to roughly 10% of sales in 2002, up from 7% in 2001, in order to help stimulate top-line growth at the ophthalmic firm
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.